Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Lynch Regenerative Medicine (LRM) Announces FDA Authorization of Two New INDs For Investigator-Initiated Clinical Trials Evaluating Injectable rhPDGF-BB for Facial Skin Quality and Treatment of Infraorbital Hollowing

      Lynch Regenerative Medicine Logo

      News provided by

      Lynch Regenerative Medicine, LLC

      Nov 18, 2026, 08:58 ET

      Share this article

      Share this article


      Research led by Michael Somenek, MD, and Sarah Allen, MD, expands LRM's clinical investigation of rhPDGF-BB in regenerative aesthetics

      FRANKLIN, Tenn., Nov. 18, 2026 /PRNewswire/ -- Lynch Regenerative Medicine, LLC (LRM), a leader in regenerative aesthetics, today announced that two new INDs for investigator-initiated studies assessing injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB or pure PDGF) in regenerative aesthetics have been accepted by the U.S. Food and Drug Administration (FDA). The study by Dr. Michael Somenek, a double board-certified facial plastic surgeon, will examine the cellular effects of rhPDGF-BB in facial skin, while the study by Dr. Sarah Allen, a double board-certified physician, Chief Medical Officer and Founder of Skin Clique, will assess its safety and efficacy when injected undereye for treatment of infraorbital hollowing (IOH).

      The announcement builds on LRM's recent IND authorization for a separate Phase IIb clinical trial evaluating injectable rhPDGF-BB for treatment of IOH. The investigator-initiated studies will explore complementary research questions, examining both the biological activity and mechanism of action of rhPDGF-BB in facial skin and its potential to improve the appearance of the under-eye area.

      "We are pleased to collaborate with these two highly regarded physicians. Dr. Somenek's study will further elucidate the mechanism of action of pure PDGF when injected specifically into facial skin, while Dr. Allen's study will complement LRM's ongoing Phase 2 multi-center trial for treatment of IOH," said Dr. Samuel Lynch, Founder and Chief Executive Officer of Lynch Regenerative Medicine. "These studies evaluate the use of pure PDGF-BB in regenerative aesthetics from complementary perspectives, examining changes in the skin at the cellular level as well as clinical outcomes when used in the under-eye area."

      Examining the Cellular Effects of rhPDGF-BB in Facial Skin

      The clinical trial led by Michael Somenek, MD, will investigate the cellular effects of rhPDGF-BB injected into facial skin in 12 participants, with skin biopsies at 7 days, 14 days, 28 days, or 8 weeks after injection to assess alterations in gene and protein expression, including changes in the natural production of collagen, elastin, and other components of the extracellular matrix. Study completion is anticipated in Q2, 2027.

      "I'm pleased to lead this investigator-initiated study examining the effects of injectable rhPDGF-BB on the skin," said Michael Somenek, MD, the study's lead investigator. "By assessing changes at the cellular level, we hope to advance the science of PDGF in aesthetics."

      Evaluating rhPDGF-BB for Treatment of Infraorbital Hollowing

      The clinical trial led by Sarah Allen, MD, will evaluate the safety and efficacy of rhPDGF-BB under eye injections for treatment of IOH in 30 participants. The study will assess the potential of pure PDGF-BB to improve skin quality, reduce the appearance of tear trough deformity and dark shadows, and improve the thickness, smoothness, and brightness of under-eye skin 12 weeks after injection. The study is anticipated to be completed in Q3, 2027.

      "Platelet-derived growth factor is not new to medicine. Our colleagues in orthopedics, oral and maxillofacial surgery, and wound care have used rhPDGF-BB for decades, and that long record of clinical experience is what has given me the confidence to study it in aesthetics," said Sarah Allen, MD, the study's lead investigator. "If we want to move aesthetic medicine forward safely, physicians and investigators must be part of the solution, and that means participating in structured clinical trials that put patient safety first. Infraorbital hollowing is one of the most common concerns patients bring to us, yet treatment options have changed very little in more than two decades. I am excited to participate in determining whether a regenerative approach has a place in treating this area."

      As a world leader in regenerative aesthetics, both studies reflect LRM's decades-long commitment to rigorous scientific research based on its rhPDGF-BB technology, which is already the most widely used tissue growth factor in regenerative medicine across multiple therapeutic and aesthetic applications. The uses of rhPDGF-BB being evaluated in these studies are investigational and have not been approved by the FDA.

      LRM separately markets ariessence pure PDGF+®, a topical cosmetic product containing rhPDGF-BB and hyaluronic acid intended to improve the appearance of skin. The injectable applications under investigation are distinct from the topical cosmetic product.

      For more information about Lynch Regenerative Medicine, visit www.lynchregen.com.

      About Lynch Regenerative Medicine, LLC
      Lynch Regenerative Medicine, LLC., (www.lynchregen.com) is a commercial stage biotech company advancing regenerative medicine through innovative therapies and aesthetic solutions. Founded by regenerative medicine and PDGF pioneer Dr. Samuel Lynch, the Company develops and commercializes recombinant growth factor products across clearly defined therapeutic indications and cosmetic applications. Its therapeutic portfolio includes (Regranex Gel®), an FDA-approved prescription biologic for promoting the healing of chronic wounds and (GEM 21S®), an FDA-approved combination product indicated for promoting regeneration of periodontal tissues. LRM also markets ariessence pure PDGF+®, a cosmetic product introduced just over two years ago, intended to improve the appearance of skin; already hundreds of thousands of people have benefitted from its topical post-procedure use (www.ariessence.com). Through its therapeutics and aesthetics companies, LRM is building a focused regenerative medicine platform grounded in scientific rigor, manufacturing expertise, a commitment to high-quality biologic innovation and improving lives. The Company is headquartered in Franklin, Tennessee.

      Contact: EvolveMKD, [email protected]

      SOURCE Lynch Regenerative Medicine, LLC

      Modal title

      Also from this source

      FDA Authorizes Lynch Regenerative Medicine's IND for a Phase IIb Clinical Trial for Injection of rhPDGF-BB for Treatment of Infraorbital Hollowing

      FDA Authorizes Lynch Regenerative Medicine's IND for a Phase IIb Clinical Trial for Injection of rhPDGF-BB for Treatment of Infraorbital Hollowing

      Lynch Regenerative Medicine, LLC (LRM), a leader in regenerative aesthetics, today announced that its Investigational New Drug (IND) application for...

      Lynch Regenerative Medicine Announces Completion of Enrollment in a Phase II Clinical Trial Evaluating rhPDGF-BB in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision

      Lynch Regenerative Medicine Announces Completion of Enrollment in a Phase II Clinical Trial Evaluating rhPDGF-BB in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision

      Lynch Regenerative Medicine, LLC ("LRM" or the "Company"), a commercial stage biotech company advancing regenerative medicine through innovative...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Cosmetics and Personal Care

      Cosmetics and Personal Care

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.